Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Autologous progenitor cells transplantation (APCT) after a high dose conditioning chemotherapy is now an established treatment modality for many hematological malignancies such as lymphoma [1]. Clinical results and survival after APCT depend on disease chemo sensitivity at transplant and the efficacy of the conditioning regimen at eradicating the residual tumor cell clone [2]. The impact of the conditioning regimen is a controversial matter and despite efforts to identify high-dose regimens with increasing antitumor activity and acceptable toxicity to normal tissues, there is not yet clear evidence of a superior conditioning platform that should be applied in the setting of recurring lymphoma patients, at least in terms of tumor-eradicating capacity.